Pharma BD Deal Intelligence

XOMA Royalty Corporation / Mural Oncology plc

2025 · Acquisition/Merger · $36M · Complete

Mural Oncology plc agreed to be acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation, for between $2.035 and $2.24 in cash per share (a base price of $2.035 plus up to $0.205 of additional consideration contingent on net cash at closing), valuing the equity at approximately $36.2 million at the base price. The transaction was implemented by Irish scheme of arrangement and closed on December 5, 2025.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals